SG10201700169PA - Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides - Google Patents

Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides

Info

Publication number
SG10201700169PA
SG10201700169PA SG10201700169PA SG10201700169PA SG10201700169PA SG 10201700169P A SG10201700169P A SG 10201700169PA SG 10201700169P A SG10201700169P A SG 10201700169PA SG 10201700169P A SG10201700169P A SG 10201700169PA SG 10201700169P A SG10201700169P A SG 10201700169PA
Authority
SG
Singapore
Prior art keywords
polypeptides
expression vector
vector element
cell generation
generation methods
Prior art date
Application number
SG10201700169PA
Inventor
Peter Michael Huelsmann
Hendrik Knoetgen
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SG10201700169PA publication Critical patent/SG10201700169PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/36—Vector systems having a special element relevant for transcription being a transcription termination element
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
SG10201700169PA 2011-12-22 2012-12-19 Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides SG10201700169PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11195361 2011-12-22

Publications (1)

Publication Number Publication Date
SG10201700169PA true SG10201700169PA (en) 2017-02-27

Family

ID=47504950

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201900915WA SG10201900915WA (en) 2011-12-22 2012-12-19 Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
SG10201700169PA SG10201700169PA (en) 2011-12-22 2012-12-19 Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
SG11201403443WA SG11201403443WA (en) 2011-12-22 2012-12-19 Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201900915WA SG10201900915WA (en) 2011-12-22 2012-12-19 Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201403443WA SG11201403443WA (en) 2011-12-22 2012-12-19 Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides

Country Status (15)

Country Link
US (2) US20160208284A1 (en)
EP (2) EP2794651B1 (en)
JP (4) JP6096802B2 (en)
KR (4) KR102048556B1 (en)
CN (4) CN113881702A (en)
BR (1) BR112014014239B1 (en)
CA (2) CA2854249C (en)
ES (1) ES2930215T3 (en)
HK (1) HK1200848A1 (en)
HR (1) HRP20221383T1 (en)
MX (2) MX355624B (en)
PL (1) PL2794651T3 (en)
RU (2) RU2639519C2 (en)
SG (3) SG10201900915WA (en)
WO (1) WO2013092743A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11046975B2 (en) 2013-10-07 2021-06-29 Prestige Biopharma Pte. Ltd. Bicistronic expression vector for antibody expression and method for producing antibody using same
CN105255867A (en) * 2015-10-19 2016-01-20 北京益生合生物科技有限公司 Gene sequence capable of preventing gradual inactivation of promoter in subculture and applications of gene sequence
JP6937309B2 (en) 2016-01-27 2021-09-22 ジャスト−エヴォテック バイオロジックス、インコーポレイテッド Hybrid promoter and its use
US11098310B2 (en) 2016-01-27 2021-08-24 Just-Evotec Biologics, Inc. Expression from transposon-based vectors and uses
US11261462B2 (en) 2016-01-27 2022-03-01 Just-Evotec Biologics, Inc. Inducible expression from transposon-based vectors and uses
BR112019007210A2 (en) 2016-10-20 2019-08-13 Sangamo Therapeutics Inc Methods and Compositions for the Treatment of Fabry Disease
JP7081139B2 (en) * 2017-12-20 2022-06-07 東ソー株式会社 New promoter and expression vector containing it
AR124712A1 (en) 2021-01-29 2023-04-26 Merck Sharp & Dohme COMPOSITIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS FOR OBTAINING THE COMPOSITIONS THEREOF
KR102640929B1 (en) 2023-06-02 2024-02-27 (주) 멥스젠 Microphysiological system forming device

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3584341D1 (en) 1984-08-24 1991-11-14 Upjohn Co RECOMBINANT DNA COMPOUNDS AND EXPRESSION OF POLYPEPTIDES LIKE TPA.
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
KR0184860B1 (en) 1988-11-11 1999-04-01 메디칼 리써어치 카운실 Single domain ligands receptors comprising said ligands methods for their production and use of said ligands
US5266491A (en) 1989-03-14 1993-11-30 Mochida Pharmaceutical Co., Ltd. DNA fragment and expression plasmid containing the DNA fragment
JP3051411B2 (en) 1989-03-14 2000-06-12 持田製薬株式会社 Novel DNA and expression plasmid containing it
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2113940T3 (en) 1990-12-03 1998-05-16 Genentech Inc ENRICHMENT METHOD FOR PROTEIN VARIANTS WITH ALTERED UNION PROPERTIES.
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
ES2206447T3 (en) 1991-06-14 2004-05-16 Genentech, Inc. HUMANIZED ANTIBODY FOR HEREGULINE.
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
RU2201449C2 (en) * 1994-10-14 2003-03-27 Сембайозис Дженетикс Инк. Fused polypeptide able to purposeful transfer to oily body, chimeric dna-construction, expressing cassette
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
DE69830315T2 (en) 1997-06-24 2006-02-02 Genentech Inc., San Francisco GALACTOSYLATED GLYCOPROTEIN CONTAINING COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
ATE419009T1 (en) 1997-10-31 2009-01-15 Genentech Inc METHODS AND COMPOSITIONS CONSISTING OF GLYCOPROTEIN GLYCOFORMS
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
ATE531812T1 (en) 1997-12-05 2011-11-15 Scripps Research Inst HUMANIZATION OF RODENT ANTIBODIES
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
AU782626B2 (en) 1999-10-04 2005-08-18 Medicago Inc. Method for regulating transcription of foreign genes
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk Process for producing polypeptide
AU784983B2 (en) 1999-12-15 2006-08-17 Genentech Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
ES2528794T3 (en) 2000-04-11 2015-02-12 Genentech, Inc. Multivalent antibodies and uses thereof
KR100408844B1 (en) 2000-07-29 2003-12-06 한국산업기술평가원 Expression vector using for animal cell
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CA2424602C (en) 2000-10-06 2012-09-18 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-producing cell
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP3523245B1 (en) 2000-11-30 2004-04-26 メダレックス，インコーポレーテッド Transgenic chromosome-introduced rodents for the production of human antibodies
NZ592087A (en) 2001-08-03 2012-11-30 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US7053202B2 (en) 2001-10-19 2006-05-30 Millennium Pharmaceuticals, Inc. Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
ES2326964T3 (en) 2001-10-25 2009-10-22 Genentech, Inc. GLICOPROTEIN COMPOSITIONS.
ATE420964T1 (en) * 2001-11-16 2009-01-15 Biogen Idec Inc POLYCISTRONIC EXPRESSION OF ANTIBODIES IN CHO CELLS
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
ATE503829T1 (en) 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd CELL WITH REDUCED OR DELETED ACTIVITY OF A PROTEIN INVOLVED IN GDP-FUCOSE TRANSPORT
US7691568B2 (en) 2002-04-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Antibody composition-containing medicament
US20040110704A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
CA2481837A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
AU2003236018A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
AU2003236019A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
DE60332957D1 (en) 2002-12-16 2010-07-22 Genentech Inc IMMUNOGLOBULIN VARIANTS AND ITS USES
CN100383244C (en) * 2003-01-07 2008-04-23 西福根有限公司 Method for manufacturing recombinant polyclonal proteins
AU2004205631A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
US20080241884A1 (en) 2003-10-08 2008-10-02 Kenya Shitara Fused Protein Composition
AU2004280065A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase
EA036531B1 (en) 2003-11-05 2020-11-19 Роше Гликарт Аг Type ii anti-cd20 humanized antibody (variants), pharmaceutical composition comprising these antibody variants, and use thereof
JPWO2005053742A1 (en) 2003-12-04 2007-06-28 協和醗酵工業株式会社 Medicament containing antibody composition
MXPA06011199A (en) 2004-03-31 2007-04-16 Genentech Inc Humanized anti-tgf-beta antibodies.
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
CA2885854C (en) 2004-04-13 2017-02-21 F. Hoffmann-La Roche Ag Anti-p-selectin antibodies
SI2116605T1 (en) * 2004-06-17 2012-07-31 Wyeth Llc Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
KR101030612B1 (en) * 2005-10-21 2011-04-20 에프. 호프만-라 로슈 아게 Method for the recombinant expression of a polypeptide
ES2577292T3 (en) 2005-11-07 2016-07-14 Genentech, Inc. Binding polypeptides with diversified VH / VL hypervariable sequences and consensus
US20070237764A1 (en) 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
CA2651567A1 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
WO2008077545A1 (en) * 2006-12-22 2008-07-03 F. Hoffmann-La Roche Ag Selection method
AU2008233196B2 (en) * 2007-03-30 2011-10-13 Abbvie Inc. Recombinant expression vector elements (rEVEs) for enhancing expression of recombinant proteins in host cells
EP1995309A1 (en) 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
CN100592373C (en) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 Liquid crystal panel drive device and its drive method
WO2009003622A1 (en) * 2007-06-29 2009-01-08 F.Hoffmann-La Roche Ag Promoter
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
PT2235064E (en) 2008-01-07 2016-03-01 Amgen Inc Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
WO2010022961A1 (en) * 2008-08-28 2010-03-04 Novartis Ag Cell surface display of polypeptide isoforms by stop codon readthrough
GB0903207D0 (en) * 2009-02-25 2009-04-08 Ucb Pharma Sa Method for expressing multimeric proteins
CA2756244A1 (en) 2009-04-02 2010-10-07 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
EP2417156B1 (en) 2009-04-07 2015-02-11 Roche Glycart AG Trivalent, bispecific antibodies
WO2010136172A1 (en) 2009-05-27 2010-12-02 F. Hoffmann-La Roche Ag Tri- or tetraspecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins

Also Published As

Publication number Publication date
HK1200848A1 (en) 2015-08-14
BR112014014239B1 (en) 2021-10-13
MX355624B (en) 2018-04-25
KR102166824B1 (en) 2020-10-19
JP6096802B2 (en) 2017-03-15
ES2930215T3 (en) 2022-12-07
JP2019030311A (en) 2019-02-28
JP2020054372A (en) 2020-04-09
PL2794651T3 (en) 2022-12-27
WO2013092743A3 (en) 2013-10-03
SG11201403443WA (en) 2014-07-30
EP2794651B1 (en) 2022-09-21
MX370481B (en) 2019-12-16
US20210024952A1 (en) 2021-01-28
EP3354660A1 (en) 2018-08-01
CA3149402A1 (en) 2013-06-27
RU2014129727A (en) 2016-02-20
KR102285184B1 (en) 2021-08-03
KR20140106585A (en) 2014-09-03
SG10201900915WA (en) 2019-03-28
RU2756910C2 (en) 2021-10-06
KR20210031002A (en) 2021-03-18
JP7096806B2 (en) 2022-07-06
CN113896787A (en) 2022-01-07
CA2854249A1 (en) 2013-06-27
CN104011075B (en) 2017-06-06
KR102048556B1 (en) 2019-11-26
JP2017108753A (en) 2017-06-22
JP6417436B2 (en) 2018-11-07
WO2013092743A2 (en) 2013-06-27
KR20190132702A (en) 2019-11-28
CA2854249C (en) 2022-05-03
US20160208284A1 (en) 2016-07-21
RU2017140661A3 (en) 2021-08-09
JP2015500656A (en) 2015-01-08
CN107119073A (en) 2017-09-01
HRP20221383T1 (en) 2023-01-06
RU2639519C2 (en) 2017-12-21
RU2017140661A (en) 2019-02-12
EP2794651A2 (en) 2014-10-29
KR20200032240A (en) 2020-03-25
BR112014014239A2 (en) 2017-12-26
MX2014007359A (en) 2014-08-01
CN113881702A (en) 2022-01-04
CN104011075A (en) 2014-08-27
KR102229491B1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
IL271870B (en) Factor viii chimeric and hybrid polypeptides, and methods of use thereof
IL260045B (en) Polypeptide constructs and uses thereof
HRP20190484T1 (en) Cell culture compositions and methods for polypeptide production
HK1200848A1 (en) Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
HK1209651A1 (en) Cells for producing recombinant iduronate-2-sulfatase -2-
IL222454B (en) Process for the production of recombinant polypeptides
HUE036147T2 (en) Polypeptide useful in adoptive cell therapy
HK1250743A1 (en) Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides
IL222453B (en) Process for the production of recombinant polypeptides
EP2935581A4 (en) Expression vectors for recombinant protein production in mammalian cells
SG11201402139UA (en) High mast2-affinity polypeptides and uses thereof
HUP1200171A1 (en) Methods for the production of polypeptides
HK1210193A1 (en) Method for the production of polypeptides in the periplasm of prokaryotic cells